Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

The Weill Family Foundation is giving $50 million to enable 4 leading research institutions to form the Weill Cancer Hub East ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop ...

The Weill Cancer Hub East brings together experts from the four institutions to improve immunotherapy, a therapeutic strategy ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

The funds will establish the Weill Cancer Hub East, a partnership among Princeton University, the Rockefeller University, Weill Cornell Medicine and the Ludwig Institute for Cancer Research aimed at ...

Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Researchers led by Israel's Weizmann Institute of Science (WIS) said cancer cells typically evade detection by displaying ...

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National ...

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...